Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Viking Therapeutics to Present at Upcoming Investor Conferences
-
Maxim Group Downgrades bluebird bio (BLUE) to Hold
-
Arch Therapeutics to Provide Corporate Update at the Maxim Group - Haitong Securities Healthcare Investor and Partnering Conference
-
Provectus Biopharmaceuticals Provides Information On Rights Offering Deadline
-
Maxim Group Starts MYnd Analytics (MYAN) at Buy
-
Maxim Group Starts Zynerba Pharmaceuticals (ZYNE) at Buy
-
Rosetta Genomics Closes Second Tranche of Previously Announced Private Placement of Convertible Debentures
-
Medley Management Inc. Announces Closing of Additional $34.5 Million Medley LLC Public Offering of 7.25% Notes Due 2024
-
Auris Medical Announces Closing of $10 Million Public Offering
-
Americans eat out less as higher menu prices take a bite from restaurant visits: Reuters/Ipsos poll
-
New Age Beverages Corporation Announces Closing of Public Offering of Common Stock
-
Maxim Group Reiterates Buy on Abeona Therapeutics (ABEO) Following ABO-102 Update
-
Maxim Group Downgrades Orchid Island Capital (ORC) to Hold Citing Valuation
-
Medley Management Inc. Announces Upsizing and Pricing of Additional $30 Million of Medley LLC 7.25% Notes Due 2024
-
Medley Management Inc. Announces Re-Opening of Public Offering of Medley LLC Notes Due 2024
-
Cytori Therapeutics, Inc. (CYTX) PT Raised to $10 at Maxim Group on Closure of the Azaya Deal
-
COPsync Announces $1.1 Million Registered Direct Offering of Common Stock
-
Auris Medical Holding (EARS) Prices 10M Shares and Warrants at $0.70/Share
-
Auris Medical Announces Pricing of $10 Million Public Offering
-
Celsion (CLSN) Sells $5M in Common stock at $0.23/Share w/Warrants
-
Celsion Corporation Announces $5.0 Million Public Offering
-
Maxim Group Downgrades Cynosure (CYNO) to Hold
-
Maxim Group Downgrades Cynosure (CYNO) to Hold
-
New Age Beverages Corporation Prices $15,000,000 Public Offering And Listing on the NASDAQ Capital Market
-
PennantPark Floating Rate Capital (PFLT) to Sell 5M Shares at $14.08
-
PennantPark Floating Rate Capital Ltd. Prices Public Offering
-
Maxim Group Reiterates Buy Rating and $4 PT on ContraVir Pharmaceuticals (CTRV); HBV Data at Upcoming Conference
-
Maxim Group Downgrades ZELTIQ Aesthetics (ZLTQ) to Hold
-
Teva Pharma (TEVA) PT Lowered to $40 at Maxim Group
-
Ritter Pharmaceuticals (RTTR) PT Raised to $5 at Maxim Group
-
Maxim Group Downgrades Pluristem Therapeutics (PSTI) to Hold
-
Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering
-
Sonoma Pharmaceuticals (SNOA) PT Raised to $9 at Maxim Group on Break Even Push
-
Interpace Diagnostics Announces Closing of $3.9 Million Public Offering
-
Maxim Group Downgrades First Community Financial (FCFP) to Hold
-
Interpace Diagnostics (IDXG) Prices 1.2M Shares at $3
-
Interpace Diagnostics Announces Pricing of Public Offering to Raise $3.6 Million
-
Interpace Diagnostics (IDXG) Plans Public Offering of Common Stock
-
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
-
Maxim Group Downgrades Galena Biopharma (GALE) to Hold
-
Athersys Announces Closing of Public Offering of Common Stock
-
Provectus Biopharmaceuticals, Inc. Announces Commencement Of Rights Offering To Existing Stockholders And Holders Of Certain Warrants
-
Cerecor (CERC) Reports ATM Equity Offering Program
-
Cerecor Announces At-the-Market Equity Offering Program
-
Athersys (ATHX) Prices 19.8M Shares at $1.01
-
Athersys Announces Pricing of Public Offering of Common Stock
-
KeyW Holding (KEYW) 8.5M Share Offering Prices at $10.50
-
KeyW Announces Pricing of Public Offering of Common Stock
-
Maxim Group Starts Mateon Therapeutics (MATN) at Buy
-
KeyW (KEYW) Announces 8.5M Public Offering of Common Stock

